• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

Chemical Profile of 1-4-(Benzyloxy)phenylethanamine (CAS No. 65746-45-4)

1-4-(Benzyloxy)phenylethanamine, identified by the Chemical Abstracts Service Number (CAS No.) 65746-45-4, is a significant compound in the realm of pharmaceutical chemistry and bioorganic synthesis. This amine derivative, characterized by its benzyloxy-substituted phenyl ring and ethylamine moiety, has garnered attention due to its structural versatility and potential applications in medicinal chemistry. The compound’s molecular framework, featuring a phenyl ring linked to an ethylamine group via a benzyloxy bridge, positions it as a valuable intermediate in the synthesis of more complex molecules, particularly in the development of pharmacologically active agents.

The structural motif of 1-4-(Benzyloxy)phenylethanamine is particularly noteworthy for its ability to modulate biological targets through steric and electronic interactions. The presence of the benzyloxy group introduces a hydrophobic pocket, which can be exploited to enhance binding affinity to specific protein receptors. Meanwhile, the amine functionality provides a site for further derivatization, allowing chemists to tailor the compound’s properties for targeted therapeutic applications. Such structural features make it a promising candidate for exploring novel drug scaffolds.

In recent years, the pharmaceutical industry has seen a surge in interest for compounds that exhibit dual functionality—capable of interacting with multiple biological pathways simultaneously. 1-4-(Benzyloxy)phenylethanamine fits this criterion well, as its dual amine and ether linkages suggest potential utility in designing molecules that can engage both enzyme and receptor targets. This dual-target engagement capability is particularly relevant in addressing complex diseases that involve multiple pathological mechanisms.

Recent advancements in computational chemistry have enabled more efficient screening of molecular libraries for drug-like properties. 1-4-(Benzyloxy)phenylethanamine has been subjected to virtual screening using molecular docking simulations to evaluate its binding affinity to various protein targets. Preliminary results indicate that this compound exhibits promising interactions with enzymes involved in metabolic pathways, suggesting its potential as an inhibitor or modulator in therapeutic contexts. Such computational studies not only accelerate the drug discovery process but also provide insights into the structural optimization of lead compounds.

The synthesis of 1-4-(Benzyloxy)phenylethanamine involves multi-step organic transformations, typically starting from commercially available aromatic precursors. The introduction of the benzyloxy group at the para position of the phenyl ring followed by functionalization at the ethyl chain presents an intriguing synthetic challenge. Modern synthetic methodologies, such as palladium-catalyzed cross-coupling reactions, have streamlined these processes, enabling higher yields and purities. The optimization of synthetic routes is crucial for scaling up production while maintaining cost-effectiveness and sustainability.

Beyond its synthetic significance, 1-4-(Benzyloxy)phenylethanamine has been explored in several preclinical studies as a potential intermediate for biologically active molecules. Researchers have investigated its derivatives for their effects on neurological disorders, inflammation, and cancer cell proliferation. For instance, modifications to the benzyloxy or amine moieties have yielded compounds with enhanced pharmacokinetic profiles and reduced toxicity. These findings underscore the importance of structure-activity relationships (SAR) in fine-tuning molecular properties for therapeutic efficacy.

The role of 1-4-(Benzyloxy)phenylethanamine in medicinal chemistry extends to its use as a building block for more complex heterocyclic systems. By incorporating this moiety into larger molecular frameworks, chemists can explore novel chemical spaces that may yield unprecedented biological activities. Heterocyclic compounds are particularly attractive in drug design due to their diverse biological interactions and favorable pharmacokinetic properties. Thus, 1-4-(Benzyloxy)phenylethanamine serves as a versatile scaffold for developing next-generation therapeutics.

Environmental considerations also play a critical role in modern pharmaceutical research. The synthesis and application of 1-4-(Benzyloxy)phenylethanamine must adhere to green chemistry principles, minimizing waste generation and hazardous byproducts. Catalytic processes and solvent recovery systems are being implemented to enhance sustainability without compromising efficiency. Such practices align with global efforts to promote environmentally responsible chemical manufacturing.

In conclusion, 1-4-(Benzyloxy)phenylethanamine (CAS No. 65746-45-4) represents a compelling compound with broad applications in pharmaceutical research and development. Its unique structural features offer opportunities for designing molecules with tailored biological activities, while advancements in synthetic methodologies continue to improve accessibility and scalability. As computational tools further refine our understanding of molecular interactions, compounds like this will remain at the forefront of drug discovery efforts aimed at addressing unmet medical needs.

• 104294-63-5(1-(4-Ethoxyphenyl)ethanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)